Advera

When ovulation stops, the o***y isn't necessarily where the problem begins.
Functional hypothalamic amenorrhea is a good example.

When hypothalamic signaling is suppressed, the effects can travel downstream through GnRH, LH, FSH, and ultimately ovarian function.
That makes kisspeptin interesting because it acts near the beginning of this reproductive signaling cascade.
Human studies have shown that kisspeptin administration can increase LH pulsatility in women with hypothalamic amenorrhea.
But there’s an important distinction:

Demonstrating a hormonal response is not the same as demonstrating restored ovulation, fertility, or pregnancy outcomes.

So rather than simply asking, “Can kisspeptin help fertility?” I think the more useful question is:
Can restoring an upstream signal meaningfully restore the reproductive rhythm downstream?

That’s where the physiology becomes much more interesting and where we need the clinical evidence to keep up with the mechanism.
For clinicians who want to explore this kind of reasoning more deeply, I cover peptide physiology and clinical application inside Peptide Therapy in Clinical Practice.

“It’s good for 28 days in the refrigerator.”
I hear versions of this often when people discuss reconstituted peptides.

But I think we need to separate two questions that frequently get treated as if they’re the same:
How long can a multidose vial be used after it has been punctured?

And:
How long does the peptide itself remain chemically stable after reconstitution?
Those are not necessarily the same timeline.

The commonly referenced 28-day period for multidose vials is primarily an infection-control recommendation.
Chemical stability depends on the molecule and formulation.
Once a peptide is in solution, oxidation can modify certain amino acids. Hydrolysis can break peptide bonds. Molecules can also aggregate.

Temperature matters. So do concentration, pH, formulation ingredients, and light exposure.
Refrigeration can slow many degradation processes, but it doesn't make them disappear.

And bacteriostatic water addresses another issue entirely: its preservative helps limit microbial growth after puncture. It doesn't automatically protect the peptide from oxidation, hydrolysis, or aggregation.
So when someone asks me:

“How long does this peptide last after I mix it?”
The date the vial was punctured is only part of the answer.
I also want to know what stability data actually exist for that peptide, at that concentration, in that formulation, under those storage conditions.

That’s a much more useful question than applying one number to every reconstituted peptide.

KPV is usually discussed for inflammation. But researchers are now looking at another potential mechanism.

What happens when KPV is introduced while new fat cells are developing?

A recent study investigated adipogenesis, the process through which immature cells become mature fat cells capable of storing lipids.

Researchers found that with KPV, fewer of those cells developed into mature fat cells, and the cells that did mature accumulated less fat.

At the highest concentration tested, one measure of fat accumulation decreased by approximately 55%, while triglyceride storage within the cells decreased by about 38%.

The researchers also studied KPV in mice consuming a high-fat diet. Those animals gained less weight and developed less white adipose tissue.

Interesting?

Absolutely.

But we need to keep the evidence in the right category.

Cell and animal findings don't establish the same effect in humans.

What they can do is help us identify mechanisms worth investigating further.

And in this case, KPV may have biology related to fat-cell development and lipid storage that goes beyond the inflammatory effects usually discussed.

For deeper education on peptide physiology and emerging research, explore Peptide Therapy in Clinical Practice.

🔗 Link in bio

If more LL-37 kills more bacteria, why not simply use more?

Because antimicrobial strength is only one side of the equation.

LL-37 is an antimicrobial peptide produced naturally by the body. Its positive charge helps attract it toward negatively charged bacterial surfaces, where it can disrupt the membrane and damage the bacterial cell.

But that activity isn't perfectly selective at every concentration.

In laboratory studies, sufficiently high concentrations of LL-37 can also begin damaging human cell membranes.

That introduces an important pharmacologic concept:

The therapeutic window.

We want enough exposure to produce the desired biological effect without creating unnecessary damage to healthy tissue.

So understanding LL-37 isn't simply about knowing that it has antimicrobial activity.

It’s understanding where antimicrobial activity and host-cell safety begin to intersect.

For deeper education on peptide physiology, dosing, safety, and clinical application, explore Peptide Therapy in Clinical Practice.

🔗 Link in bio

Not everything marketed as an “oral peptide” belongs in the same category as clinical peptide therapy.

That's an important distinction with products like MAKE Wellness.

These are dietary supplements, essentially nutraceuticals, containing peptide ingredients derived from sources including fava bean, ginseng, ginkgo, yeast, and whey.

Can those ingredients contain peptides?

Absolutely.

But the word “peptide” simply describes short chains of amino acids. Its presence doesn't automatically make a supplement equivalent to a defined therapeutic peptide.

When clinicians discuss molecules such as semaglutide, ipamorelin, or BPC-157, we're talking about specific molecular structures with their own pharmacology, dosing, and molecule-specific research.

So the question shouldn't simply be:

“Does this product contain peptides?”

It should also be:

“What exactly is the molecule, and what evidence do we have for that specific product or ingredient?”

Same terminology. Very different categories.

For deeper education on peptide science and clinical application, explore Peptide Therapy in Clinical Practice.

🔗 Link in bio

We usually talk about NAD in terms of cellular energy. But what if part of the story is also mitochondrial cleanup?

Damaged mitochondria can accumulate inside neurons in Parkinson’s disease.

Normally, cells have a quality-control process called mitophagy that identifies dysfunctional mitochondria and removes them.

Recent research in Parkinson’s models found that increasing NAD supported this process.

Researchers observed improved mitochondrial function, reduced inflammatory signaling, and protection of dopamine-producing neurons.

That gives us a different way to think about NAD.

Not simply as something involved in energy production, but potentially as part of the cellular systems responsible for maintaining mitochondrial quality.

The distinction is important: these findings come from disease models and should not be interpreted as evidence that NAD has been proven to treat Parkinson’s disease in humans.

But mechanistically, it’s a fascinating area to follow.

For deeper education on NAD physiology and clinical integration, explore Peptide Therapy in Clinical Practice.

🔗 Link in bio

Peptide or biologic? With retatrutide, the answer could have consequences far beyond what we call the molecule.

Retatrutide has 39 amino acids in its main peptide chain, while Lilly has argued that its broader structure should place it within the regulatory definition applicable to biological products.

That distinction matters because the two categories can follow very different regulatory routes.

If treated as a peptide drug, future competing versions would generally enter through the generic drug pathway after the relevant protections expire.

If treated as a biologic, competitors would instead generally pursue a biosimilar pathway, with a different approval and exclusivity structure.

Then there's compounding.

Biological products aren't eligible for the usual federal 503A and 503B drug-compounding exemptions.

So the retatrutide classification dispute raises much bigger questions:

What route could future competitors use?

How would exclusivity apply?

And could the drug ever be compounded under the conventional federal compounding framework?

Sometimes a regulatory definition can have very practical consequences.

🔗 Learn more inside Peptide Therapy in Clinical Practice. Link in bio.

Your peptide vial looks perfectly clear. Does that mean the peptide is still behaving exactly as it should?

Not necessarily.

Peptides can undergo aggregation, where individual molecules begin sticking together and forming clusters.

That can happen during manufacturing, storage, transportation, and after reconstitution.

Some of these aggregates can be microscopic, which means you can't reliably identify them just by looking at the vial.

And that distinction matters.

Aggregation can alter how the peptide behaves, and larger molecular clusters may also be recognized differently by the immune system, potentially contributing to anti-drug antibody formation.

So visual inspection has limits.

A clear vial tells us what we can see. It doesn't tell us everything about peptide stability or molecular integrity.

That's an important distinction when we're talking about product quality in peptide therapy.

For deeper education on peptide stability, product quality, and clinical application, explore Peptide Therapy in Clinical Practice.

🔗 Link in bio